Patents Examined by Niloofar Rahmani
  • Patent number: 10703735
    Abstract: The invention provides novel 4-phenyl-coumarin derivatives, processes for their preparation and uses thereof as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: July 7, 2020
    Assignees: Lead Discovery Center GmbH, Max Planck Gesellschaft zur Förderung der Wissenschaften e. V.
    Inventors: Raffaella Di Lucrezia, Tim Bergbrede, Peter Nussbaumer, Uwe Koch, Bert Klebl, Axel Choidas, Anke Unger, Nils-Göran Larsson, Maria Falkenberg-Gustafsson, Claes M. Gustafsson
  • Patent number: 10696689
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: June 30, 2020
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Sangdon Han, Sun Hee Kim, Yunfei Zhu
  • Patent number: 10696666
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: June 30, 2020
    Assignee: CELLCENTRIC LIMITED
    Inventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
  • Patent number: 10682413
    Abstract: The present invention relates to a pharmaceutical composition and a lyophilisate of a diazabicyclooctane derivative represented by Compound I, a process for producing the same and methods for using the same.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: June 16, 2020
    Assignees: FEDORA PHARMACEUTICALS INC., MEIJI SEIKA PHARMA CO., LTD.
    Inventor: Kewei Yang
  • Patent number: 10683274
    Abstract: The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is —CO—, —SO2— and the like; R1 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkylcarbonyl group and the like; R2 is an optionally-substituted C1-6 alkyl group, an optionally-substituted C1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R3, R4, R5, and R6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 16, 2020
    Assignee: Boston Biomedical, Inc.
    Inventors: Toshihiko Sone, Wataru Hirose, Naoaki Shimada, Chiang Li, Wei Li, David Leggett
  • Patent number: 10675281
    Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: June 9, 2020
    Assignee: Celgene Corporation
    Inventors: Matthew D. Alexander, Gerald D. Artman, III, Matthew D. Correa, Joshua Hansen, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Paula A. Tavares-Greco, Brandon W. Whitefield, Nanfei Zou
  • Patent number: 10669268
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, Y, A, W, R2, m, n, p and q are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: June 2, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jerome Hert, Daniel Hunziker, Patrizio Mattei, Harald Mauser, Guozhi Tang, Lisha Wang
  • Patent number: 10667518
    Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: June 2, 2020
    Assignee: Syngenta Participations AG
    Inventors: Pierre Joseph Marcel Jung, Andrew Edmunds, Michel Muehlebach
  • Patent number: 10668047
    Abstract: Provided herein are compounds of formula (I)-(VI): wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: June 2, 2020
    Assignee: Molecular Templates, Inc.
    Inventors: Mark Matteucci, Xiaohong Cai, Yeyu Cao, Hailong Jiao, Jing Yuan Ma, Jian-Xin Duan
  • Patent number: 10647710
    Abstract: Disclosed in the present invention are a new thiazole compound, particularly a compound represented by formula (I), a pharmaceutical composition thereof and applications thereof in the preparation of drugs for the treatment of diseases related to herpes simplex viruses.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: May 12, 2020
    Assignee: Medshine Discovery Inc.
    Inventors: Haiying He, Zhigan Jiang, Weihua Shi, Jianhua Xia, Jian Li, Shuhui Chen
  • Patent number: 10647714
    Abstract: Disclosed herein are 5 or 8-substituted imidazo[1,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[1,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo[1,5-a]pyridines that can be useful for inhibiting indoleamine 2,3-dioxygenase and/or tryptophane 2,3-dioxygenase and for treating diseases or disorders mediated thereby.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: May 12, 2020
    Assignee: BEIGENE, LTD.
    Inventors: Hexiang Wang, Guoliang Zhang, Yunhang Guo, Bo Ren, Zhiwei Wang, Changyou Zhou
  • Patent number: 10640481
    Abstract: The present invention is directed to methods for preparing Beraprost and novel synthetic intermediates for Beraprost.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: May 5, 2020
    Assignee: Lung Biotechnology PBC
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Sri Harsha Tummala, Raju Penmasta, David A. Walsh
  • Patent number: 10640496
    Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: May 5, 2020
    Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATION
    Inventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
  • Patent number: 10632209
    Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: April 28, 2020
    Assignee: The Regents of the University of Michigan
    Inventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
  • Patent number: 10633366
    Abstract: The present invention relates to novel antibacterial compounds (1) as defined below, pharmaceutical compositions containing them and their use as antimicrobials. A compound of formula (1): A-L1-Y-L2-R—B, wherein A is a cyclic group having one of the following formulae (I), (II) and (III), and wherein B is cyclic group having one of the following formulae (IV) to (IX).
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: April 28, 2020
    Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Rosella Ombrato, Gabriele Magaro, Barbara Garofalo, Guido Furlotti, Giorgina Mangano, Alessandra Capezzone De Joannon
  • Patent number: 10633371
    Abstract: The present disclosure provides compounds of any one of Formulae (I), (II), and (III). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: April 28, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Joshiawa Paulk, Jun Qi
  • Patent number: 10618908
    Abstract: The present invention provides a compound having the structure:
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: April 14, 2020
    Assignee: Lixte Biotechnology, Inc.
    Inventors: John S. Kovach, Robert Volkmann, Anthony Marfat
  • Patent number: 10611749
    Abstract: The present invention relates to a novel process for the preparation of Rotigotine of formula (I) and intermediates thereof.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 7, 2020
    Assignee: Solara Active Pharma Sciences Limited
    Inventors: Victor Paul Raj Irudayaraj, Senthilkumar Subramani, Vedhachalam Govindaraj, Jeyakanthan Jayavelu, Boopathy Jayaraman, Uttam Kumar Ray, Tangirala Vittal
  • Patent number: 10611772
    Abstract: The present invention provides a novel crystalline form of Ribociclib succinate, Ribociclib succinate Form APO-I, including Ribociclib succinate, benzyl alcohol and water, compositions thereof, processes for the preparation thereof, and the use of this crystalline form in the treatment of conditions associated with increased CDK4/6 kinase activity, and in particular, cancers, including certain forms of breast cancer.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: April 7, 2020
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Bahareh Khalili
  • Patent number: 10611751
    Abstract: The invention provides certain (phenyl)-(pyrazol)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, or a pharmaceutically acceptable salt thereof, to treat certain symptoms of Parkinson's disease, schizophrenia, ADHD or Alzheimer's disease.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: April 7, 2020
    Assignee: Eli Lilly and Company
    Inventors: Darryl Wayne Hilliard, Junliang Hao, David Andrew Coates